2018
DOI: 10.1093/ntr/nty063
|View full text |Cite
|
Sign up to set email alerts
|

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders

Abstract: Accumulating data from preclinical studies and clinical trials suggest that drugs targeting CNS cholinergic systems may be useful for symptomatic treatment of movement disorders. Nicotinic cholinergic drugs, including nicotine and selective nAChR receptor agonists, reduce L-dopa-induced dyskinesias, as well as antipsychotic-induced tardive dyskinesia, and may be useful in Tourette's syndrome and ataxia. Subtype selective muscarinic cholinergic drugs may also provide effective therapies for Parkinson's disease,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
40
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 29 publications
(41 citation statements)
references
References 209 publications
(264 reference statements)
1
40
0
Order By: Relevance
“…GABA-ergic projection neurons, MSNs, express nicotinic receptors only to a very limited extent (Bordia and Perez, 2019; Loonen et al, 2019). The influence of nAChRs on neurotransmitter release from glutamatergic and dopaminergic terminals suggests a possible role in the pathogenesis and treatment of certain movement disorders (particularly levodopa-induced dyskinesia); this is supported by available evidence (Quik et al 2019). The effects of drugs antagonising muscarinic receptors, however, largely surpass those of substances which affect nAChRs and are therefore considered in this article in more detail.…”
Section: Cholinergic Receptorsmentioning
confidence: 82%
“…GABA-ergic projection neurons, MSNs, express nicotinic receptors only to a very limited extent (Bordia and Perez, 2019; Loonen et al, 2019). The influence of nAChRs on neurotransmitter release from glutamatergic and dopaminergic terminals suggests a possible role in the pathogenesis and treatment of certain movement disorders (particularly levodopa-induced dyskinesia); this is supported by available evidence (Quik et al 2019). The effects of drugs antagonising muscarinic receptors, however, largely surpass those of substances which affect nAChRs and are therefore considered in this article in more detail.…”
Section: Cholinergic Receptorsmentioning
confidence: 82%
“…[58,59]. There is also emerging research that suggest that nicotine and other drugs that act as nicotinic acetylcholine receptors (nAChRs) may be beneficial in the management of Parkinson’s disease, Alzheimer’s, and related neurological disorders, making the large-scale production of highly purified nicotine at low costs for therapeutics necessary [60,61].…”
Section: Introductionmentioning
confidence: 99%
“…With elaboration of complex neurotransmitter interactions in the basal ganglia and novel agents becoming available to target specific receptor subtypes, future trials may yet confirm selective muscarinic or nicotinic agents that could reduce TD movements [ 105 , 110 - 112 ]. Given the dense localization of muscarinic receptors (mAChRs) in the striatum, they may constitute a viable target affecting TD [ 110 , 113 ].…”
Section: Pharmacotherapy Of Tardive Dyskinesiamentioning
confidence: 99%
“…The role of diminished nicotinic receptor (nAChR) function underlying TD is suggested by the fact that D2-receptor blockade may result in reduced binding and loss of nAChRs [ 105 ]. Since activation of nAChR normally evokes release of striatal dopamine, nicotinic agonists should acutely worsen TD, but long-term administration leading to nAChR desensitization may reduce dopamine release and potentially suppress dyskinesias [ 111 , 114 ]. In fact, chronic administration of nicotine does indeed attenuate haloperidol-induced vacuous chewing movements in rodent and primate models [ 115 , 116 ].…”
Section: Pharmacotherapy Of Tardive Dyskinesiamentioning
confidence: 99%